标题
Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes
作者
关键词
Glucagon-like peptide-1 receptor agonists, Insulin, Patient compliance, Type 2 diabetes
出版物
ADVANCES IN THERAPY
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2019-01-04
DOI
10.1007/s12325-018-0868-9
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial
- (2018) Liana K. Billings et al. DIABETES CARE
- More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L
- (2018) Juan Frias et al. DIABETES OBESITY & METABOLISM
- Low Incidence of Gastrointestinal Adverse Events Over Time with a Fixed-Ratio Combination of Insulin Glargine and Lixisenatide vs Lixisenatide Alone
- (2018) Jennifer M. Trujillo et al. DIABETES OBESITY & METABOLISM
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2018 EXECUTIVE SUMMARY
- (2018) Alan J. Garber et al. Endocrine Practice
- Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations
- (2018) Ian Blumer et al. POSTGRADUATE MEDICINE
- Anticipatory guidance in type 2 diabetes to improve disease management; next steps after basal insulin
- (2018) Eric L. Johnson et al. POSTGRADUATE MEDICINE
- Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA
- (2018) Lawrence Blonde et al. Diabetes Therapy
- Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA
- (2018) Lawrence Blonde et al. Diabetes Therapy
- Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis
- (2017) Xiaoling Cai et al. EXPERT OPINION ON PHARMACOTHERAPY
- Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
- (2017) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical inertia to insulin initiation and intensification in the UK: A focused literature review
- (2017) Kamlesh Khunti et al. Primary Care Diabetes
- An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin
- (2017) Marc Evans et al. JOURNAL OF MEDICAL ECONOMICS
- Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes
- (2017) Virginia Valentine et al. Diabetes Therapy
- iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L
- (2017) Elisabeth Niemoeller et al. Diabetes Therapy
- Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes
- (2017) Virginia Valentine et al. Diabetes Therapy
- iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L
- (2017) Elisabeth Niemoeller et al. Diabetes Therapy
- Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
- (2017) Mirko Sikirica et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Insulin Glargine/Lixisenatide Fixed Ratio Combination Improves Glycemic Variability in Type 2 Diabetes
- (2016) Ronnie Aronson et al. Canadian Journal of Diabetes
- Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus
- (2016) Kristy Iglay et al. CURRENT MEDICAL RESEARCH AND OPINION
- Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial
- (2016) Julio Rosenstock et al. DIABETES CARE
- Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial
- (2016) Vanita R. Aroda et al. DIABETES CARE
- Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
- (2016) Michael Nauck et al. DIABETES CARE
- Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial
- (2016) H. W. Rodbard et al. DIABETIC MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial
- (2016) Sultan Linjawi et al. Diabetes Therapy
- The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial
- (2016) Sultan Linjawi et al. Diabetes Therapy
- Polypharmacy in elderly patients with type 2 diabetes receiving oral antidiabetic treatment
- (2015) Marianna Noale et al. ACTA DIABETOLOGICA
- Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
- (2015) Juris J. Meier et al. DIABETES CARE
- One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial
- (2015) S. C. L. Gough et al. DIABETES OBESITY & METABOLISM
- Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes
- (2015) H. W. Rodbard et al. DIABETES OBESITY & METABOLISM
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY – CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN – 2015
- (2015) Yehuda Handelsman et al. Endocrine Practice
- How much is too much? Outcomes in patients using high-dose insulin glargine
- (2015) T. Reid et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
- (2014) Julio Rosenstock et al. DIABETES CARE
- Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
- (2014) John B. Buse et al. DIABETES CARE
- Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
- (2014) Michaela Diamant et al. DIABETES CARE
- Time to do more: Addressing clinical inertia in the management of type 2 diabetes mellitus
- (2014) W.D. Strain et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes
- (2014) Stephen C L Gough et al. Lancet Diabetes & Endocrinology
- Relationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones
- (2013) C. S. Marathe et al. DIABETES CARE
- Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
- (2013) C. Kapitza et al. DIABETES OBESITY & METABOLISM
- Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study
- (2012) M. Peyrot et al. DIABETES OBESITY & METABOLISM
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Correlates of Insulin Injection Omission
- (2010) M. Peyrot et al. DIABETES CARE
- Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
- (2010) R. E. Ratner et al. DIABETIC MEDICINE
- Participants’ experiences of intensifying insulin therapy during the Treating to Target in Type 2 Diabetes (4-T) trial: qualitative interview study
- (2010) N. Jenkins et al. DIABETIC MEDICINE
- How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes
- (2010) S. Arnolds et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Incretin-Based Therapies: Viewpoints on the way to consensus
- (2009) Michael. A. Nauck et al. DIABETES CARE
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now